1.1.1.141: 15-hydroxyprostaglandin dehydrogenase (NAD+)
This is an abbreviated version!
For detailed information about 15-hydroxyprostaglandin dehydrogenase (NAD+), go to the full flat file.
Word Map on EC 1.1.1.141
-
1.1.1.141
-
cox-2
-
cyclooxygenase-2
-
fetal
-
arachidonic
-
pregnancy
-
chorion
-
labor
-
pgf2alpha
-
indomethacin
-
parturition
-
nsaid
-
trophoblast
-
preterm
-
myometrium
-
chemoprevention
-
15-keto
-
eicosanoids
-
thromboxane
-
prostanoids
-
decidua
-
synthase-1
-
nadp-linked
-
15-keto-pge2
-
clubbing
-
cesarean
-
osteoarthropathy
-
prostacyclin
-
amnion
-
beta-hydroxysteroid
-
lipoxins
-
calcitriol
-
9-ketoreductase
-
medicine
-
slco2a1
-
6-keto-pgf1
-
drug development
- 1.1.1.141
- cox-2
- cyclooxygenase-2
- fetal
-
arachidonic
- pregnancy
- chorion
- labor
-
pgf2alpha
- indomethacin
-
parturition
-
nsaid
- trophoblast
-
preterm
- myometrium
-
chemoprevention
-
15-keto
-
eicosanoids
-
thromboxane
-
prostanoids
- decidua
- synthase-1
-
nadp-linked
-
15-keto-pge2
-
clubbing
-
cesarean
- osteoarthropathy
- prostacyclin
- amnion
-
beta-hydroxysteroid
-
lipoxins
- calcitriol
-
9-ketoreductase
- medicine
-
slco2a1
-
6-keto-pgf1
- drug development
Reaction
Synonyms
11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD+ 15-oxidoreductase, 15-hydroxy prostaglandin dehydrogenase, 15-hydroxy-prostaglandin-dehydrogenase, 15-hydroxyprostaglandin dehydrogenase, 15-hydroxyprostaglandin-dehydrogenase, 15-hydroxyprostanoic dehydrogenase, 15-OH-PGDH, 15-PGDH, 15-prostaglandin dehydrogenase, dehydrogenase, 15-hydroxyprostaglandin, HPGD, NAD+ dependent 15-hydroxyprostaglandin dehydrogenase, NAD+ dependent PGDH, NAD+-15-hydroxy prostanoate oxidoreductase, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (type I), NAD+-dependent 15-PGDH, NAD+-linked 15-hydroxyprostaglandin dehydrogenase, NAD-dependent 15-hydroxyprostaglandin dehydrogenase, NAD-specific 15-hydroxyprostaglandin dehydrogenase, nicotinamide adenine dinucleotide-dependent 15-hydroxyprostaglandin dehydrogenase, PGDH, prostaglandin dehydrogenase
ECTree
1.1.1.141 15-hydroxyprostaglandin dehydrogenase (NAD+)Advanced search results
results (
results (Source Tissue
Source Tissue on EC 1.1.1.141 - 15-hydroxyprostaglandin dehydrogenase (NAD+)
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
SOURCE TISSUE 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
SOURCE
-
non-small cell lung carcinoma cell line A549, expression of 15-PGDH is induced by dexamethason, prednisolone, betamethasone and triamcinolone
-
both 15-hydroxyprostaglandin dehydrogenase mRNA and protein levels are significantly higher in kidney cortex than in papilla. Enzyme is mainly localized to the tubular epithelial cells in kidney cortex and outer medulla
-
55000 Da form of enzyme, level increases with preterm premature rupture of membrane
15-hydroxyprostaglandin dehydrogenase is expressed mainly in keratinocytes and melanocytes
invasiveapocrine carcinoma cells correspond to a distinct molecular subtype of breast carcinomas characterized by the expression of 15-prostaglandin dehydrogenase alone or in combination with a novel form of acyl-CoA synthetase medium-chain family member 1, 15-prostaglandin dehydrogenase is not expressed by other breast cancer types
in hair follicle, 15-hydroxyprostaglandin dehydrogenase is expressed mainly in keratinocytes and melanocytes
-
intense immunofluorescent staining for 15-hydroxyprostaglandin dehydrogenase in macula densa and glomerulus of cyclooxygenase-2 knock-out mice
in hair follicle, 15-hydroxyprostaglandin dehydrogenase is expressed mainly in keratinocytes and melanocytes
-
macula densa cell line, significantly lower enzyme levels than in a proximal tubule cell line. Treatment with an inhibitor of cyclooxygenase-2 increases enzyme level
-
intense immunofluorescent staining for 15-hydroxyprostaglandin dehydrogenase in macula densa and glomerulus of cyclooxygenase-2 knock-out mice
-
enzyme is mainly localized to the tubular epithelial cells in kidney cortex and outer medulla
the enzyme is expressed mainly in the glandular epithelium, enzyme activity during the oestrous cycle and early pregnancy, overview
-
PGDH messenger RNA (mRNA) abundance decreases significantly in the visceral yolk sac membrane and the amnion throughout the last third of pregnancy
additional information
-
up-regulation of cyclooxygenase-2 expression by pro-inflammatory cytokines is accompanied by down-regluation of 15-hydroxyprostaglandin dehydrogenase expression. Over-expression of cyclooxygenase-2 but not -1 also attenuates 15-hydroxyprostaglandin dehydrogenase expression. Similarly, overexpression of 15-hydroxyprostaglandin dehydrogenase inhibits interleukin 1beta-induced cyclooxygenase-2 expression and results in apoptosis. The levels of 15-hydroxyprostaglandin dehydrogenase expression in transfected cells correlate positively with those of mesenchymal markers, and negatively with those of epithelial markers
-
expression of the enzyme and the estrogen receptor is correlated
-
in preterm chorion, levles of 15-hydroxyprostaglandin dehydrogenase protein and activity are lower when compared to term, and are further reduced with the presence of infection. Preterm premature rapture of membranes and subclinical inflammation do not affect the levels of 29000 Da 15-hydroxyprostaglandin dehydrogenase protein in the fetal membranes
-
distribution of enzyme expression within the tissue in situ, overview
-
-
highly reduced enzyme expression in colon cancers, distribution of enzyme expression within the tissue in situ, overview
-
highly reduced enzyme expression in colon cancers, distribution of enzyme expression within the tissue in situ, overview
-
-
intense immunofluorescent staining for 15-hydroxyprostaglandin dehydrogenase in macula densa and glomerulus of cyclooxygenase-2 knock-out mice
generation of transgenic mice with targeted expression of 15-hydroxyprostaglandin dehydrogenase in the liver
-
loss of 15-hydroxyprostaglandin expression in 65% of lung cancers. Enzyme acts as a tumor suppressor in lung cancer
-
NSCLC cell, much lower expression of 15-hydroxyprostaglandin dehydrogenase in all NSCLC histologic groups compared with healthy lung cell. Treatment with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib increases the expression of the enzyme in a subset of NSCLC lines
-
reduced expression of 15-PGDH occurrs in tumor cells and is paralleled by decreased 15-PGDH activity in tumors
-
the amount of 15-PGDH is frequently decreased in NSCLC cells compared with adjacent normal lung
-
-
285914, 285915, 285916, 285919, 285920, 285922, 285923, 285927, 285932, 285933, 285934, 285935, 285937, 654361, 657210, 711448
-
PGDH protein is concentrated in the parietal yolk sac membrane (PYS) lining the placental surface and in placental blood vessels
-
androgen-sensitive cancer cells LNCaP and hormone-independent PC3 cells, enzyme expression is induced by steroids
additional information
-
distribution of enzyme expression in normal and pathological tissues, overview, no enzyme expression in spleen, heart, HCT-116 cells, CacO-2 cells and Colo 201 cells
additional information
-
enzyme expression analysis, PGDH expression is repressed in multiple human cancers
additional information
-
tissue distribution of enzyme expression, overview, no expression in heart and brain
additional information
-
a 42- to 55-fold induction of the PGDH activity is observed after 20 days of gestation in pregnant rabbits
